Furthermore, it is known that certain patient groups are more responsive to FSH treatment than others, depending on their genetic background [153] and other associated factors, suggesting the possibility of pharmacogenetic approaches to individualized infertility treatments. This evidence concerns the gene BRD2 and Infertility.